Cargando...
Hyperprogression to a dual immune blockade followed by subsequent response with cabozantinib in metastatic poor-risk clear cell renal cell carcinoma with NOTCH mutation
Currently, more and more patients receive first-line treatment with immunotherapy combinations and not all patients respond in metastatic renal cell carcinoma. After IO-IO progression, we don’t have a standard of treatment because it is not available prospective data on this setting. We present the...
Gardado en:
| Publicado en: | Oncotarget |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Impact Journals LLC
2020
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7275785/ https://ncbi.nlm.nih.gov/pubmed/32547710 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.27598 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|